A pilot trial of the combination of vemurafenib with adoptive cell therapy in patients with metastatic melanoma

Clinical Cancer Research

Volumn 23, Issue 2, 2017, Pages 351-362

  Deniger, Drew C ^a   Kwong, Mei Li M ^a   Pasetto, Anna ^a   Dudley, Mark E ^b   Wunderlich, John R ^a   Langhan, Michelle M ^a   Lee, Chyi Chia Richard ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Cell and Gene Therapy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDESLEUKIN; BILIRUBIN; CALCIUM ION; CREATININE; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MAGNESIUM ION; PHOSPHATE; POTASSIUM ION; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CANCER RADIOTHERAPY; CANCER SURGERY; CELL VIABILITY; CELLULITIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GENE; GINGIVA DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; INFECTION; KLEBSIELLA PNEUMONIAE; LYMPH NODE DISSECTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MAGNESIUM BLOOD LEVEL; MALE; METASTATIC MELANOMA; MICROCOCCUS LUTEUS; MIDDLE AGED; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; OLIGURIA; PARTIAL THROMBOPLASTIN TIME; PHOSPHATE BLOOD LEVEL; PILOT STUDY; POTASSIUM BLOOD LEVEL; QT PROLONGATION; RASH; RHINOVIRUS; SIDE EFFECT; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS EPIDERMIDIS; T LYMPHOCYTE; TCRB GENE; THROMBOCYTOPENIA; THROMBUS; TUMOR ASSOCIATED LEUKOCYTE; WHOLE BODY RADIATION; WIDE EXCISION; YOUNG ADULT; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; HIGH THROUGHPUT SEQUENCING; MELANOMA; METASTASIS; MUTATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; CELL PROLIFERATION; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDOLES; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES; T-LYMPHOCYTES;

EID: 85011105194     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0906     Document Type: Article

References (42)

1. DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. Devita, Hellman, and Rosenberg's cancer: principles & practice of oncology. 10th ed. Philadelphia: Wolters Kluwer; 2015.
2. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348:62-8.
3. Kwong ML, Neyns B, Yang JC. Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy. Clin Cancer Res 2013;19:5292-9.
4. Lizee G, Overwijk WW, Radvanyi L, Gao J, Sharma P, Hwu P. Harnessing the power of the immune system to target cancer. Annu Rev Med 2013;64:71-90.
5. +-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 2013;31:2152-9.
6. Phan GQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control 2013;20:289-97.
7. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
8. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7.
9. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012;18:6758-70.
10. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 2013;19:4792-800.
11. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res 2010;16:2646-55.
12. Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol 2016; 34:2389-97.
13. Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 2014;32:2248-54.
14. Swaika A, Crozier JA, Joseph RW. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des Devel Ther 2014;8:775-87.
15. Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S, Windhovel S, et al. Vemurafenib induces senescence features in melanoma cells. J Invest Dermatol 2013;133:1601-9.
16. Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. Clin Cancer Res 2011;17:1658-63.
17. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
18. Ravnan MC, Matalka MS. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma. Clin Ther 2012;34:1474-86.
19. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
20. Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, et al. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. Eur J Cancer 2015;51:1435-43.
21. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19:1225-31.
22. Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, et al. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology 2013;2:e26615.
23. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition ofmelanoma without affecting lymphocyte function. Cancer Res 2010;70:5213-9.
24. George AL, Suriano R, Rajoria S, Osso MC, Tuli N, Hanly E, et al. PLX4032 mediated melanoma associated antigen potentiation in patient derived primary melanoma cells. J Cancer 2015;6:1320-30.
25. Deniger DC, Pasetto A, Tran E, Parkhurst MR, Cohen CJ, Robbins PF, et al. Stable, nonviral expression of mutated tumor neoantigen-specific T-cell receptors using the sleeping beauty transposon/transposase system. Mol Ther 2016;24:1078-89.
26. Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 2010;23:820-7.
27. Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res 2010;16:6040-8.
28. Grippo JF, Zhang W, Heinzmann D, Yang KH, Wong J, Joe AK, et al. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutationpositive metastatic melanoma. Cancer Chemother Pharmacol 2014;73: 103-11.
29. Stewart JJ, Lee CY, Ibrahim S, Watts P, Shlomchik M, Weigert M, et al. A Shannon entropy analysis of immunoglobulin and T cell receptor. Mol Immunol 1997;34:1067-82.
30. Six A, Mariotti-Ferrandiz ME, Chaara W, Magadan S, Pham HP, Lefranc MP, et al. The past, present, and future of immune repertoire biology - the rise of next-generation repertoire analysis. Front Immunol 2013;4:413.
31. Acquavella N, Clever D, Yu Z, Roelke-Parker M, Palmer DC, Xi L, et al. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol Res 2015;3:37-47.
32. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013;19:393-403.
33. Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer 2015;51:2792-9.
34. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-9.
35. Wong DJ, Ribas A. Targeted therapy for melanoma. Cancer Treat Res 2016;167:251-62.
36. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 2014; 15:954-65.
37. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371:1867-76.
38. Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res 2015;21:1639-51.
39. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer 2015;51:833-40.
40. Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372:30-9.
41. Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux AL, et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol Res 2014;2:351-60.
42. Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015; 37:764-82.